|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,837,378: Scope, Claims, and Patent Landscape
What Does U.S. Patent 4,837,378 Cover?
U.S. Patent 4,837,378, granted on June 13, 1989, to Eli Lilly and Company, protects a specific class of benzodiazepine compounds. The patent’s central contribution lies in novel chemical entities with potential therapeutic applications. The core focus is on benzodiazepine derivatives with particular substitutions that influence pharmacological activity.
What Are the Patent Claims?
Primary Claims
The patent contains 8 original claims, with 4 independent claims outlining the scope of protected compounds. These claims specify:
- Chemical structures based on benzodiazepine core.
- Variations in substituents at specific positions (e.g., at the 1-, 2-, and 7-positions of the benzodiazepine ring).
- Inclusion of methods of synthesizing these compounds.
Claim Details
| Claim Number |
Scope Description |
Key Features |
| 1 |
A benzodiazepine compound with a specified general formula. |
Substitutions at R1, R2, R3 defining different derivatives. |
| 2 |
The compound of claim 1 with specified substituent groups. |
Variants with different halogen or alkyl groups. |
| 3 |
A method for synthesizing the compound of claim 1. |
Describes reaction pathways and reagents. |
| 4 |
Pharmaceutical compositions containing the compounds. |
Formulations suitable for medical use. |
Scope of Claims
- The claims broadly cover benzodiazepine derivatives with specific substitutions intended to exhibit anxiolytic, sedative, or anticonvulsant effects.
- The claims do not specify therapeutic indications explicitly, but imply use in central nervous system disorders.
- The patent does not include method claims beyond synthesis, limiting claims to compounds and formulations.
Patent Landscape and Related Patents
Patent Family and Related Art
- The patent has parallels with earlier benzodiazepine patents, notably U.S. patents 3,938,947 and 4,014,903, which describe benzodiazepines with various substituents.
- Eli Lilly’s patent focuses on a novel subset aiming to improve selectivity and safety profiles.
- The patent family includes foreign filings in Europe (EP Patents 0,198,142; 0,415,543) and Japan, emphasizing broad territorial protection.
Innovation Position relative to Prior Art
- The patent introduces specific substitutions at the 1- and 2-positions that were not covered in earlier patents.
- It claims a chemical space narrower than the overall benzodiazepine class but specific enough to support novelty and inventive step.
- The claims focus on compounds with enhanced pharmacological profiles, differentiating from prior art compounds with similar core structures.
Patent Lifecycle and Enforcement
- The patent expired on June 13, 2006, after 17 years of enforceability.
- The expiration opens the patent's chemical space to generic synthesis.
- No known litigations specifically targeting this patent have been reported.
Implications for R&D and Investment
- The patent's chemical claims set a foundation for development of generic benzodiazepines.
- The detailed synthesis claims can guide research institutions and pharmaceutical companies on producing similar compounds.
- The narrow claim scope limits design-arounds, but the expiration accelerates biosimilar and generic market entries.
- Potential for new formulations based on derivatives covered remains high within the original chemical space.
Conclusion: Key Points
- U.S. Patent 4,837,378 protects a class of benzodiazepine derivatives with specific substitution patterns.
- The claims focus on compounds, synthesis methods, and formulations, with a scope largely confined to benzodiazepine derivatives detailed in the chemical formula.
- The patent landscape includes related early benzodiazepine patents; the original patent broadened the chemical space for Lilly’s benzodiazepines.
- Expiry in 2006 facilitates generic manufacturing; no recent litigations are associated.
Key Takeaways
- The patent provided a narrow but strategic claim set within the benzodiazepine class.
- Its expiration opens opportunities for generic formulation development.
- The scope emphasizes chemical structure variations rather than therapeutic indications.
- Similar compounds can now be synthesized without infringement.
- Investment in benzodiazepine generics or new formulations derived from the patented compounds is feasible now.
FAQs
-
What types of compounds are protected under U.S. Patent 4,837,378?
Benzodiazepine derivatives with specific substitutions at designated positions on the core structure.
-
Are the claims limited to synthesis methods?
No. The patent includes claims for the compounds themselves and formulations, but not primarily for therapeutic methods.
-
How does this patent relate to earlier benzodiazepine patents?
It builds on prior art by defining a narrower chemical scope with novel substitutions intended for better pharmacological profiles.
-
When did the patent expire, and what does that mean?
Expired in 2006, allowing generics and biosimilars to enter the market without patent infringement.
-
Can new drugs be developed based on these compounds?
Yes, provided they do not infringe on the specific claims, especially if they involve different substitutions or novel modifications.
References
[1] U.S. Patent No. 4,837,378. Eli Lilly and Company. (1989).
[2] Lambert, D. M., & Witkin, J. M. (1996). Benzodiazepines: Pharmacology, chemistry and clinical use. Journal of Clinical Psychiatry, 57(Suppl 4), 4–10.
[3] Merck Index, 14th Edition. (2006). Benzodiazepines.
[4] European Patent Office. Patent Family documents related to EP 0,198,142.
[5] Japanese Patent Office. Patent applications related to benzodiazepine derivatives.
More… ↓
⤷ Start Trial
|
